{"entity":{"id":"nct07446270","kind":"trial","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","aka":[],"tldr":"A phase 2 trial of cetuximab and nimotuzumab in pancreatic cancer, run by Chinese PLA General Hospital, not yet recruiting.","summary":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies is a phase 2, interventional study registered as NCT07446270 by Chinese PLA General Hospital, with a registry enrolment figure of 90 participants, started 2026-03-03 and due to reach its primary completion in 2027-10-30. Interventions recorded: Colorectal cancer: Tunlametinib + cetuximab β; Pancreatic cancer: Tunlametinib + cetuximab β; Pancreatic cancer: Tunlametinib +Nimotuzumab. Conditions listed: Treatment for Advanced Colorectal Cancer; Treatment for Advanced Pancreatic Cancer. Primary outcome: ORR. Pancreatic eligibility wording from the registry: \"Patients with histologically or pathologically confirmed advanced pancreatic cancer or advanced colorectal cancer who have failed standard therapy;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07446270","url":"https://clinicaltrials.gov/study/NCT07446270"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["cetuximab","nimotuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07446270","phase":"2","setting":"A Cohort Clinical Study to Evaluate the Efficacy and Safety of Tunlametinib Combined With Anti-EGFR Monoclonal Antibody in Patients With RAS-mutated Advanced Gastrointestinal Malignancies","sponsor":"Chinese PLA General Hospital","participation":[{"nct":"NCT07446270","source":"https://clinicaltrials.gov/study/NCT07446270","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"6dbab5a74b2838179fa6e45e116de313437acb1b2f1819ef44bc8a2322adadee","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-03-03","leadSponsor":"Chinese PLA General Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":90,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-03-03","startedType":"estimated","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07446270/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}